ZA202006346B - Pharmaceutical preparation - Google Patents
Pharmaceutical preparationInfo
- Publication number
- ZA202006346B ZA202006346B ZA2020/06346A ZA202006346A ZA202006346B ZA 202006346 B ZA202006346 B ZA 202006346B ZA 2020/06346 A ZA2020/06346 A ZA 2020/06346A ZA 202006346 A ZA202006346 A ZA 202006346A ZA 202006346 B ZA202006346 B ZA 202006346B
- Authority
- ZA
- South Africa
- Prior art keywords
- pharmaceutical preparation
- pharmaceutical
- preparation
- Prior art date
Links
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180050277A KR101992400B1 (en) | 2018-04-30 | 2018-04-30 | Pharmaceutical formulation |
PCT/KR2019/005151 WO2019212214A1 (en) | 2018-04-30 | 2019-04-29 | Pharmaceutical preparation |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA202006346B true ZA202006346B (en) | 2022-01-26 |
Family
ID=67055715
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA2020/06346A ZA202006346B (en) | 2018-04-30 | 2020-10-13 | Pharmaceutical preparation |
Country Status (9)
Country | Link |
---|---|
KR (1) | KR101992400B1 (en) |
CN (1) | CN112040933A (en) |
MX (1) | MX2020010259A (en) |
PH (1) | PH12020551547A1 (en) |
RU (1) | RU2756452C1 (en) |
SG (1) | SG11202009187YA (en) |
TW (1) | TWI697339B (en) |
WO (1) | WO2019212214A1 (en) |
ZA (1) | ZA202006346B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102595702B1 (en) * | 2021-06-09 | 2023-10-30 | 주식회사 보령 | Pharmaceutical composite formulation and method of preparing pharmaceutical composite formulation |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101336922A (en) * | 2008-08-08 | 2009-01-07 | 青岛黄海制药有限责任公司 | Rosuvastatin amlodipine composition |
US8535715B2 (en) * | 2009-11-13 | 2013-09-17 | Bristol-Myers Squibb Company | Bilayer tablet formulations |
KR101058284B1 (en) | 2010-01-22 | 2011-08-22 | 보령제약 주식회사 | Novel Process for the Preparation of 2- (2-N-butyl-4-hydroxy-6-methyl-pyrimidin-5-yl) -N, N-dimethylacetamide |
KR101168136B1 (en) * | 2011-08-08 | 2012-07-24 | 보령제약 주식회사 | Antihypertensive pharmaceutical composition |
MX362400B (en) * | 2012-03-30 | 2019-01-16 | Dae Woong Pharma | Pharmaceutical composition comprising olmesartan medoxomil and rosuvastatin or its salt. |
CN103156842B (en) * | 2013-03-08 | 2014-05-28 | 南开大学 | Novel application of Arctigenin in preparation of anti-arrhythmia medicine |
SG11201507305SA (en) * | 2013-03-14 | 2015-10-29 | Boryung Pharm | Pharmaceutical combination drug |
KR101910901B1 (en) * | 2013-11-29 | 2018-10-24 | 한미약품 주식회사 | Pharmaceutical complex formulation comprising amlodipine, losartan and rosuvastatin |
ES2882672T3 (en) * | 2015-07-08 | 2021-12-02 | Hk Inno N Corp | Pharmaceutical composition containing amlodipine, valsartan, and rosuvastatin |
WO2017091041A1 (en) * | 2015-11-26 | 2017-06-01 | 보령제약 주식회사 | Novel salt of fimasartan |
-
2018
- 2018-04-30 KR KR1020180050277A patent/KR101992400B1/en active Active
-
2019
- 2019-04-29 TW TW108114949A patent/TWI697339B/en not_active IP Right Cessation
- 2019-04-29 MX MX2020010259A patent/MX2020010259A/en unknown
- 2019-04-29 CN CN201980029029.3A patent/CN112040933A/en active Pending
- 2019-04-29 WO PCT/KR2019/005151 patent/WO2019212214A1/en active Application Filing
- 2019-04-29 RU RU2020138708A patent/RU2756452C1/en active
- 2019-04-29 SG SG11202009187YA patent/SG11202009187YA/en unknown
-
2020
- 2020-09-24 PH PH12020551547A patent/PH12020551547A1/en unknown
- 2020-10-13 ZA ZA2020/06346A patent/ZA202006346B/en unknown
Also Published As
Publication number | Publication date |
---|---|
SG11202009187YA (en) | 2020-10-29 |
KR101992400B1 (en) | 2019-06-24 |
RU2756452C1 (en) | 2021-09-30 |
TW201946916A (en) | 2019-12-16 |
WO2019212214A1 (en) | 2019-11-07 |
CN112040933A (en) | 2020-12-04 |
PH12020551547A1 (en) | 2021-06-07 |
TWI697339B (en) | 2020-07-01 |
MX2020010259A (en) | 2020-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL276232A (en) | Pharmaceutical compounds | |
GB2572126B (en) | Pharmaceutical | |
GB2569961B (en) | Pharmaceutical | |
GB2572125B (en) | Pharmaceutical | |
GB201807942D0 (en) | Pharmaceutical formulation | |
GB201810245D0 (en) | Pharmaceutical compounds | |
GB201810239D0 (en) | Pharmaceutical compounds | |
GB201819961D0 (en) | Pharmaceutical compounds | |
GB201819960D0 (en) | Pharmaceutical compounds | |
ZA202102871B (en) | Pharmaceutical formulation | |
GB201703876D0 (en) | Pharmaceutical combinations | |
IL278927A (en) | Pharmaceutical formulation | |
ZA202006570B (en) | Pharmaceutical formulations | |
GB201807053D0 (en) | Pharmaceutical composition | |
GB201801562D0 (en) | Pharmaceutical compounds | |
IL269239A (en) | Pharmaceutical combination comprising ponesimod | |
IL277334A (en) | Pharmaceutical combinations | |
GB201901989D0 (en) | Pharmaceutical combinations | |
GB201808571D0 (en) | Pharmaceutical compositions | |
IL279334A (en) | Pharmaceutical combinations | |
GB201800378D0 (en) | Pharmaceutical compounds | |
ZA202006541B (en) | Pharmaceutical composition comprising brexpiprazole | |
SG11202103374TA (en) | Pharmaceutical composition | |
SG11202010792TA (en) | Improved pharmaceutical formulations | |
GB201816369D0 (en) | Pharmaceutical compounds |